Atossa wins U.S. patent related to multiple formulation of lead asset
Source: SeekingAlpha
2025-04-30 14:40:35 ET
More on Atossa Therapeutics
- Atossa Therapeutics, Inc. (ATOS) Q4 2024 Earnings Call Transcript
- Atossa Therapeutics announces issuance of U.S. patent
- Seeking Alpha’s Quant Rating on Atossa Therapeutics
- Historical earnings data for Atossa Therapeutics
- Financial information for Atossa Therapeutics
Read the full article on Seeking Alpha
For further details see:
Atossa wins U.S. patent related to multiple formulation of lead asset
Atossa Therapeutics Inc.
NASDAQ: ATOS
ATOS Trading
-2.35% G/L:
$4.98 Last:
5,103 Volume:
$5.11 Open:
ATOS Latest News
May 14, 2026 08:30:00 am
Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast CancerMay 08, 2026 08:45:00 am
Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate UpdateATOS Stock Data
$42,239,054
7,796,787
11.03%
15
N/A
Biotechnology & Life Sciences
Healthcare
US
Seattle
